Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria

[1]  L. Ranganath,et al.  Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling , 2021, JIMD reports.

[2]  J. Jarvis,et al.  Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. , 2020, The lancet. Diabetes & endocrinology.

[3]  N. Deutz,et al.  Nitisinone causes acquired tyrosinosis in alkaptonuria , 2020, Journal of inherited metabolic disease.

[4]  J. Jarvis,et al.  Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria , 2020, Journal of inherited metabolic disease.

[5]  A. Milan,et al.  Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria , 2019, Scientific Reports.

[6]  A. Milan,et al.  Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. , 2018, Molecular genetics and metabolism.

[7]  D. Dykhuizen,et al.  Evolutionary implications of Liebig's law of the minimum: Selection under low concentrations of two nonsubstitutable nutrients , 2017, Ecology and evolution.

[8]  F. Eyskens,et al.  Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls , 2016, Orphanet Journal of Rare Diseases.

[9]  L. Ranganath,et al.  Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry , 2015, Annals of clinical biochemistry.

[10]  Andrea Zatkova,et al.  Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte , 2014, Annals of the rheumatic diseases.

[11]  P. McKiernan.  Nitisinone for the treatment of hereditary tyrosinemia type I , 2013 .

[12]  R. Rauh,et al.  Diurnal variation of phenylalanine and tyrosine concentrations in adult patients with phenylketonuria: subcutaneous microdialysis is no adequate tool for the determination of amino acid concentrations , 2013, Nutrition Journal.

[13]  J. Leonard,et al.  Recommendations for the management of tyrosinaemia type 1 , 2013, Orphanet Journal of Rare Diseases.

[14]  J. Troendle,et al.  A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. , 2011, Molecular genetics and metabolism.

[15]  M. Ichinose,et al.  Estimation of protein intake using urinary urea nitrogen in patients with early-stage liver cirrhosis , 2007, Hepatology international.

[16]  William A Gahl,et al.  Natural history of alkaptonuria. , 2002, The New England journal of medicine.

[17]  E. Lock,et al.  From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug , 1998, Journal of Inherited Metabolic Disease.

[18]  R. Wolfe,et al.  Exercise-induced changes in protein metabolism. , 1998, Acta physiologica Scandinavica.

[19]  D. Millward.  Human amino acid requirements. , 1997, The Journal of nutrition.

[20]  E. Lock,et al.  Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. , 1996, Toxicology and applied pharmacology.

[21]  E. Lock,et al.  Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. , 1995, Toxicology and applied pharmacology.

[22]  S. Lindstedt,et al.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase , 1992, The Lancet.

[23]  J. Henriksson.  Effect of exercise on amino acid concentrations in skeletal muscle and plasma. , 1991, The Journal of experimental biology.

[24]  J. J. Bunim,et al.  Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: Review of world literature (1584–1962) , 1963 .

[25]  L. Ranganath,et al.  Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria. , 2015, JIMD reports.

[26]  J. Jarvis,et al.  Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. , 2014, JIMD reports.

[27]  G. Mitchell.  Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. , 1996, Human & experimental toxicology.

[28]  W. Mitch,et al.  A method for estimating nitrogen intake of patients with chronic renal failure. , 1985, Kidney international.